Pharma news
Pharma
Dispute hinges on clauses set out in decade-old settlement and licensing agreement | Federal Circuit unpersuaded by arguments suggesting that a federal court erred in denying a preliminary injunction. 4 January 2024
Pharma
District judge ruled in favour of Regeneron confirming patent infringement by Mylan | Court recognised Mylan's success in challenging the validity of certain patents | Ruling happened while Regeneron filed a separate case against another competitor alleging the infringement of 51 patents. 2 January 2024
Pharma
Life science attorneys should see some notable developments relating to artificial intelligence, patent eligibility and the Fintiv rule, write Manita Rawat and Alexander Stein of Morgan Lewis. 2 January 2024
Pharma
CureVac suffers a blow following a favourable earlier opinion delivered by the German Federal Patent Court | Decision invalidates a patent related to mRNA tech. 21 December 2023
Pharma
The Biden administration’s proposals target price gouging triggers resistance | The move, which includes the consideration of march-in rights for taxpayer-funded drugs, may ‘jeopardise collaborative partnerships and hinder innovation. 19 December 2023
Pharma
Court rules that patent must be later-filed to be available as OTDP reference | MSN had submitted ANDA for generic version of Parkinson’s treatment Nuplazid. 14 December 2023
Pharma
US government takes on price gouging in latest raft of proposals | IP attorney says the “unfortunate decision” will deter future public-private collaboration | Move prompts concern over government's future use of march-in rights. 12 December 2023
Asia
A Korean district court has applied a landmark ruling in a complicated vaccine dispute involving Pfizer, explain Young Kim, Yu-Seog WON, In Hwan Kim, and Amy Oh of Kim & Chang. 12 December 2023
Pharma
Hearing is latest in dispute between the biotech research firms | Multi-jurisdictional case concerns patents relating to the in-situ detection of analytes. 12 December 2023
Pharma
Case dismissed with settlement between Novartis and Daiichi Sankyo unit | Melanoma therapy at centre of feud after Novartis faced infringement claims over Tafinlar. 7 December 2023